<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04570670</url>
  </required_header>
  <id_info>
    <org_study_id>BLS-11-104</org_study_id>
    <nct_id>NCT04570670</nct_id>
  </id_info>
  <brief_title>Comparative Bioavailability of BAFIERTAM™ (Monomethyl Fumarate) and Tecfidera® (Dimethyl Fumarate) in Healthy Subjects</brief_title>
  <official_title>A Single-Dose, Randomized, Open-Label, 2-Way Crossover, Comparative Bioavailability Study of BLS-11 (Monomethyl Fumarate) 190 mg and Tecfidera (Dimethyl Fumarate) 240 mg in Healthy Male and Female Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Banner Life Sciences LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Banner Life Sciences LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study was to assess the bioequivalence of the test product&#xD;
      (Bafiertam; BLS-11; monomethyl fumarate) 190 mg versus Tecfidera® (dimethyl fumarate) 240 mg&#xD;
      based on the Cmax and Area Under the Curve (AUC) values of monomethyl fumarate (MMF)&#xD;
      determined after a single dose under fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a single-dose, open-label, randomized, 2-way crossover study, evaluating the&#xD;
      comparative pharmacokinetics of the test product (MMF) versus the reference product (DMF)&#xD;
      under fasting conditions. Fifty (50) healthy, adult male and non-pregnant female subjects&#xD;
      were enrolled. Screening of subjects occurred within 21 days prior to the first dose.&#xD;
      Subjects were randomized to 1 of 2 treatment sequences prior to the first dose.&#xD;
&#xD;
      In each period, subjects received a single oral dose of MMF 190 mg administered as two 95 mg&#xD;
      delayed-release capsules (test product) or Tecfidera® 240 mg DMF delayed-release capsule&#xD;
      (reference product), followed by blood sampling (including predose samples) up to 24 hours&#xD;
      postdose for the determination of plasma concentrations of MMF. There was a washout period of&#xD;
      2 days between the 2 doses.&#xD;
&#xD;
      Safety was monitored throughout the study by repeated clinical and laboratory evaluations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 6, 2017</start_date>
  <completion_date type="Actual">February 17, 2017</completion_date>
  <primary_completion_date type="Actual">February 17, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Subjects were randomized to 1 of 2 treatment sequences prior to the first dose.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Bioequivalent (BE) Comparison of AUC0-inf of Monomethyl Fumarate (MMF) Between Treatments</measure>
    <time_frame>24 hours</time_frame>
    <description>Pharmacokinetics: Plasma concentrations of MMF will be determined and used to calculate AUC0-inf MMF for each treatment. Venous blood samples were collected immediately prior to dosing (time 0), and then 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 11, 12, and 24 hours postdose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The BE Comparison of Cmax of Monomethyl Fumarate (MMF) Between Treatments</measure>
    <time_frame>24 hours</time_frame>
    <description>Pharmacokinetics: Plasma concentrations of MMF will be determined and used to calculate the Cmax of MMF for each treatment.Venous blood samples were collected immediately prior to dosing, and then 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 11, 12, and 24 hours postdose.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Relapsing Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Test (BLS-11)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral dose administration of BLS-11 190 mg (2 × 95 mg monomethyl fumarate delayed-release capsules) at Hour 0 on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference (Tecfidera)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single oral dose administration of Tecfidera 240 mg (1 × 240 mg dimethyl fumarate delayed-release capsule) at Hour 0 on Day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>monomethyl fumarate 190 mg</intervention_name>
    <arm_group_label>Test (BLS-11)</arm_group_label>
    <other_name>BAFIERTAM</other_name>
    <other_name>BLS-11</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dimethyl fumarate 240 mg</intervention_name>
    <arm_group_label>Reference (Tecfidera)</arm_group_label>
    <other_name>Tecfidera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Continuous non-smoker who had not used nicotine-containing products for at least 3&#xD;
             months prior to the first dose and throughout the study.&#xD;
&#xD;
          2. Body mass index (BMI) ≥ 18.5 and ≤ 29.9 kg/m2 at Screening.&#xD;
&#xD;
          3. Medically healthy as determined by the Investigator or designee with no clinically&#xD;
             significant medical history, physical examination, laboratory profiles, vital signs or&#xD;
             electrocardiograms (ECGs), as deemed by the Investigator or designee.&#xD;
&#xD;
          4. Females of childbearing potential: not pregnant and either sexually inactive&#xD;
             (abstinent) for 14 days prior to the first dose and throughout the study or using one&#xD;
             of the following acceptable birth control methods: hormonal oral contraceptives,&#xD;
             vaginal ring, transdermal patch, or nonhormone or hormone releasing intrauterine&#xD;
             device for at least 3 months prior to the first dose with either a physical (e.g.,&#xD;
             condom, diaphragm, or other) or a chemical (e.g., spermicide) barrier method from the&#xD;
             time of Screening and throughout the study; depot/implantable hormone (e.g., Depo&#xD;
             Provera®, Implanon®) for at least 3 months prior to the first dose and throughout the&#xD;
             study.&#xD;
&#xD;
             In addition, female subjects of childbearing potential were advised to remain sexually&#xD;
             inactive or to keep the same birth control method for at least 7 days following the&#xD;
             last dose.&#xD;
&#xD;
          5. Females of non-childbearing potential: had undergone one of the following&#xD;
             sterilization procedures at least 6 months prior to the first dose: hysteroscopic&#xD;
             sterilization; bilateral tubal ligation or bilateral salpingectomy; hysterectomy;&#xD;
             bilateral oophorectomy or were postmenopausal with amenorrhea for at least 1 year&#xD;
             prior to the first dose and follicle-stimulating hormone (FSH) serum levels consistent&#xD;
             with postmenopausal status as per Investigator's or designee's judgment.&#xD;
&#xD;
          6. Non-vasectomized male subjects agreed to use a condom with spermicide or abstain from&#xD;
             sexual intercourse during the study until 90 days beyond the last dose of study drug.&#xD;
             (No restrictions were required for a vasectomized male provided his vasectomy had been&#xD;
             performed 4 months or more prior to the first dose of study drug. A male who had been&#xD;
             vasectomized less than 4 months prior to the first dose of study drug, followed the&#xD;
             same restrictions as a non-vasectomized male.)&#xD;
&#xD;
          7. Males agreed not to donate sperm from the first dose until 90 days after dosing.&#xD;
&#xD;
          8. Understood the study procedures in the Informed Consent Form (ICF), and were willing&#xD;
             and able to comply with the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject was mentally or legally incapacitated or had significant emotional problems at&#xD;
             the time of the Screening visit or expected during the conduct of the study.&#xD;
&#xD;
          2. History or presence of clinically significant medical or psychiatric condition or&#xD;
             disease in the opinion of the Investigator or designee.&#xD;
&#xD;
          3. History of any illness that, in the opinion of the Investigator or designee, might&#xD;
             have confounded the results of the study or posed an additional risk to the subject by&#xD;
             their participation in the study.&#xD;
&#xD;
          4. History or presence of alcoholism or drug abuse within the past 2 years prior to the&#xD;
             first dose.&#xD;
&#xD;
          5. History or presence of hypersensitivity or idiosyncratic reaction to the study drugs&#xD;
             or related compounds.&#xD;
&#xD;
          6. Female subjects with a positive serum pregnancy test at Screening or Check-in, or who&#xD;
             were lactating.&#xD;
&#xD;
          7. Positive urine drug, alcohol, or cotinine results at Screening or Check-in.&#xD;
&#xD;
          8. Positive results at Screening for human immunodeficiency virus (HIV), hepatitis B&#xD;
             surface antigen (HBsAg) or hepatitis C virus (HCV).&#xD;
&#xD;
          9. Seated blood pressure was less than 90/40 mmHg or greater than 140/90 mmHg at&#xD;
             Screening.&#xD;
&#xD;
         10. Seated heart rate was lower than 40 beats per minute (bpm) or higher than 99 bpm at&#xD;
             Screening.&#xD;
&#xD;
         11. Abnormal 12-lead ECG deemed clinically significant by the Investigator or designee at&#xD;
             Screening or prior to the first dose.&#xD;
&#xD;
         12. Unable to refrain from or anticipated the use of any drug, including prescription and&#xD;
             non-prescription medications, or herbal remedies, beginning 14 days prior to the first&#xD;
             dose and throughout the study. Medication listed as part of acceptable birth control&#xD;
             methods was allowed. Hormone replacement therapy was also allowed. Acetaminophen (up&#xD;
             to 2 g per 24-hour period) may have been permitted, as necessary during the study.&#xD;
&#xD;
         13. Had been on a diet incompatible with the on study diet, in the opinion of the&#xD;
             Investigator or designee, within the 28 days prior to the first dose and throughout&#xD;
             the study.&#xD;
&#xD;
         14. Donation of blood or significant blood loss within 30 days prior to the first dose.&#xD;
&#xD;
         15. Plasma donation within 7 days prior to the first dose.&#xD;
&#xD;
         16. Participation in another clinical study within 28 days prior to the first dose. The&#xD;
             28-day window was derived from the date of the last blood collection or dosing,&#xD;
             whichever was later, in the previous study to Day 1 of Period 1 of the current study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franck Rousseau, MD</last_name>
    <role>Study Director</role>
    <affiliation>Banner Life Sciences LLC</affiliation>
  </overall_official>
  <link>
    <url>https://rdcu.be/chVM1</url>
    <description>Open Access</description>
  </link>
  <results_reference>
    <citation>Lategan TW, Wang L, Sprague TN, Rousseau FS. Pharmacokinetics and Bioavailability of Monomethyl Fumarate Following a Single Oral Dose of Bafiertam™ (Monomethyl Fumarate) or Tecfidera(®) (Dimethyl Fumarate). CNS Drugs. 2021 May;35(5):567-574. doi: 10.1007/s40263-021-00799-9. Epub 2021 Mar 30.</citation>
    <PMID>33797063</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 22, 2020</study_first_submitted>
  <study_first_submitted_qc>September 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2020</study_first_posted>
  <results_first_submitted>April 28, 2021</results_first_submitted>
  <results_first_submitted_qc>July 27, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 28, 2021</results_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dimethyl Fumarate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 12, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/70/NCT04570670/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Randomized Sequence AB</title>
          <description>Treatment A: A single oral dose of BLS-11 190 mg (2 x 95 mg)&#xD;
Treatment B: A single oral dose of Tecfidera® 240 mg (1 × 240 mg)</description>
        </group>
        <group group_id="P2">
          <title>Randomized Sequence BA</title>
          <description>Treatment B: A single oral dose of Tecfidera® 240 mg (1 × 240 mg)&#xD;
Treatment A: A single oral dose of BLS-11 190 mg (2 x 95 mg)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Randomization Sequence AB</title>
          <description>Treatment A: A single oral dose of BLS-11 190 mg (2 x 95 mg) MMF&#xD;
Treatment B: A single oral dose of Tecfidera® 240 mg (1 × 240 mg) DMF</description>
        </group>
        <group group_id="B2">
          <title>Randomization Sequence BA</title>
          <description>Treatment B: A single oral dose of Tecfidera® 240 mg (1 × 240 mg) DMF&#xD;
Treatment A: A single oral dose of BLS-11 190 mg (2 x 95 mg) MMF</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.4" spread="9.85"/>
                    <measurement group_id="B2" value="38.0" spread="8.22"/>
                    <measurement group_id="B3" value="36.2" spread="9.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.98" spread="9.450"/>
                    <measurement group_id="B2" value="74.78" spread="12.512"/>
                    <measurement group_id="B3" value="74.78" spread="11.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168.6" spread="7.55"/>
                    <measurement group_id="B2" value="170.3" spread="10.58"/>
                    <measurement group_id="B3" value="169.5" spread="9.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (kg/m^2)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.625" spread="2.4142"/>
                    <measurement group_id="B2" value="25.678" spread="2.9237"/>
                    <measurement group_id="B3" value="25.651" spread="2.6537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Bioequivalent (BE) Comparison of AUC0-inf of Monomethyl Fumarate (MMF) Between Treatments</title>
        <description>Pharmacokinetics: Plasma concentrations of MMF will be determined and used to calculate AUC0-inf MMF for each treatment. Venous blood samples were collected immediately prior to dosing (time 0), and then 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 11, 12, and 24 hours postdose.</description>
        <time_frame>24 hours</time_frame>
        <population>One subject in the Reference (Tecfidera) group was excluded from AUC0-inf calculations because of missing or unreportable values and was excluded from the statistical analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Test (BLS-11)</title>
            <description>A single oral dose administration of BLS-11 190 mg (2 × 95 mg monomethyl fumarate delayed-release capsules) at Hour 0 on Day 1&#xD;
monomethyl fumarate 190 mg</description>
          </group>
          <group group_id="O2">
            <title>Reference (Tecfidera)</title>
            <description>A single oral dose administration of Tecfidera 240 mg (1 × 240 mg dimethyl fumarate delayed-release capsule) at Hour 0 on Day 1&#xD;
dimethyl fumarate 240 mg</description>
          </group>
        </group_list>
        <measure>
          <title>The Bioequivalent (BE) Comparison of AUC0-inf of Monomethyl Fumarate (MMF) Between Treatments</title>
          <description>Pharmacokinetics: Plasma concentrations of MMF will be determined and used to calculate AUC0-inf MMF for each treatment. Venous blood samples were collected immediately prior to dosing (time 0), and then 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 11, 12, and 24 hours postdose.</description>
          <population>One subject in the Reference (Tecfidera) group was excluded from AUC0-inf calculations because of missing or unreportable values and was excluded from the statistical analyses.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2984" spread="25.9"/>
                    <measurement group_id="O2" value="3116" spread="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The BE Comparison of Cmax of Monomethyl Fumarate (MMF) Between Treatments</title>
        <description>Pharmacokinetics: Plasma concentrations of MMF will be determined and used to calculate the Cmax of MMF for each treatment.Venous blood samples were collected immediately prior to dosing, and then 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 11, 12, and 24 hours postdose.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Test (BLS-11)</title>
            <description>A single oral dose administration of BLS-11 190 mg (2 × 95 mg monomethyl fumarate delayed-release capsules) at Hour 0 on Day 1&#xD;
monomethyl fumarate 190 mg</description>
          </group>
          <group group_id="O2">
            <title>Reference (Tecfidera)</title>
            <description>A single oral dose administration of Tecfidera 240 mg (1 × 240 mg dimethyl fumarate delayed-release capsule) at Hour 0 on Day 1&#xD;
dimethyl fumarate 240 mg</description>
          </group>
        </group_list>
        <measure>
          <title>The BE Comparison of Cmax of Monomethyl Fumarate (MMF) Between Treatments</title>
          <description>Pharmacokinetics: Plasma concentrations of MMF will be determined and used to calculate the Cmax of MMF for each treatment.Venous blood samples were collected immediately prior to dosing, and then 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 11, 12, and 24 hours postdose.</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1760" spread="34.8"/>
                    <measurement group_id="O2" value="1680" spread="33.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Test (BLS-11)</title>
          <description>A single oral dose administration of BLS-11 190 mg (2 × 95 mg monomethyl fumarate delayed-release capsules) at Hour 0 on Day 1&#xD;
monomethyl fumarate 190 mg</description>
        </group>
        <group group_id="E2">
          <title>Reference (Tecfidera)</title>
          <description>A single oral dose administration of Tecfidera 240 mg (1 × 240 mg dimethyl fumarate delayed-release capsule) at Hour 0 on Day 1&#xD;
dimethyl fumarate 240 mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (19.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Feeling Hot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Vessel puncture site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Vessel puncture site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Vessel puncture site swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Euphoric mood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Thomas Lategan, PhD</name_or_title>
      <organization>Banner Life Sciences LLC</organization>
      <phone>3368990959</phone>
      <email>thomas.lategan@bannerls.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

